RxDoctor Payments DataLook up a doctor →

Jason Anast, MD

Urology · Overland Park, KSNPI 1114045358

Payments from drug & device makers

$31,484in general payments, 2019–2025

Across 374 payments — averaging $84.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teleflex LLC$23K
  • Neotract Inc.$1K
  • Valencia Technologies Corporation$1K
  • AbbVie$812
  • Antares Pharma, Inc.$597
  • Medtronic$407
  • plus $4K from 44 others

What the payments were for

  • Consulting fees$3,75012%
  • Speaking & faculty fees$14,68847%
  • Travel & lodging$4,39614%
  • Food & beverage$8,48327%
  • Education$1681%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$31,484 in reported general payments places this provider in the 85th percentile of 111 urology providers in Kansas.

See all urology providers in Kansas

Medicare billing

Part B allowed, 2024
$385,358
Medicare patients
782
Services billed
8,260

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron112$92,414
MyrbetriqMirabegron124$66,508
XyostedTestosterone Enanthate15$18,677
Potassium Citrate ErPotassium Citrate89$7,857
Tamsulosin Hcl513$7,153
Trospium Chloride127$5,731
Finasteride334$5,007
Desmopressin Acetate75$4,108
Tolterodine Tartrate ErTolterodine Tartrate54$3,918
Methenamine Hippurate39$2,738
Solifenacin Succinate71$2,496
Fesoterodine Fumarate ErFesoterodine Fumarate30$2,366
Silodosin30$2,048
Estradiol24$1,618
NitrofurantoinNitrofurantoin Macrocrystal47$1,454

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$152$92,414112 claims
Astellas Pharma US IncMyrbetriq$349$66,508124 claims
Antares Pharma, Inc.Xyosted$597$18,67715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 111 urology providers in Kansas.

Other urology in Overland Park

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →